Navigation Links
Nucleoside in Medical Technology

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

... more potent than Pharmasset's first generation nucleoside polymerase inhibitor, RG7128 (formerly known as ... toxicities that may be associated with some nucleoside analogs. Like RG7128, PSI-7851 has demonstrated ... clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... of R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency ... of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV ... protease inhibitor, with InterMune, and R7128, a nucleoside polymerase inhibitor, with Pharmasset. ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development ... support the efficacy and safety of R7128, and nucleoside polymerase inhibitors as a class," said Michelle ... Pharmasset's Chief Medical Officer. "We believe nucleoside inhibitors have a number of advantages over other ...

Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)

... About PSI-7851 PSI-7851 is a uridine nucleoside analog currently in developed for the treatment ... metabolite of Pharmasset's first generation nucleoside polymerase inhibitor, R7128. In vitro studies ... toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in ...

Pharmasset Receives Notice of Allowance

... No. 10/828,753 titled, "Modified Fluorinated nucleoside Analogues," covering the composition of matter of ... property rights in our growing pipeline of HCV nucleoside polymerase inhibitors," stated Schaefer Price, ... is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug ...

Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)

... this week in Milan, Italy. Second-Generation nucleoside Polymerase Inhibitor Program IDX184 is a ... potency than the first-generation HCV nucleoside clinical drug candidates currently in ... "The preclinical profiles emerging in our HCV nucleoside and protease inhibitor programs are very ...

Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients

... Risk of Toxicity Associated with nucleoside Class of HIV Drugs KENILWORTH, N.J., April 15 ... Truvada is a combination product in the nucleoside reverse transcriptase inhibitor (NRTI) class. ... 356: 1723-35. 9 The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of ...

Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C

... R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is ... that there appear to be certain synergies between nucleoside polymerase inhibitors and the standard of care ... is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug ...

Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference

... in San Francisco, CA. Second-Generation nucleoside Polymerase Inhibitor Program Idenix's preclinical HCV nucleoside polymerase inhibitor program comprises two novel ... technology, which delivers high levels of nucleoside triphosphate in the liver, potentially ...

Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART

... of our knowledge, this is the first example of a nucleoside analog triphosphate showing non-competitive inhibition. Potent Antiviral Activity of the nucleoside HCV Inhibitor, R7128, in Prior IFN ... early evidence of high genetic barrier for nucleoside inhibitors of NS5B polymerase. The safety and ...

R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients

... R7128 is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being ... antiviral drug combinations, and nucleoside polymerase inhibitors such as R7128 could improve ... potent antiviral activity of any investigational nucleoside HCV polymerase inhibitor to date in ...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

... liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic ...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

... for rheumatoid arthritis as well." Thiarabine is a next generation nucleoside analogue that Access has licensed from Southern Research. It has been in ... and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in ...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

... download from the journal's website. "Thiarabine is a next generation nucleoside analogue, licensed by Access from Southern Research Institute ," stated ... factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in ...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also show ... to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors, and non-nucleosides that, through virtue of binding at a ...

Pharmasset Reports Fiscal Year End 2008 Financial Results

... progress with our hepatitis C virus (HCV) programs. R7128, our lead HCV nucleoside inhibitor, completed 28 day clinical studies in both treatment naive and ... treatment. These efforts provide the groundwork for our next generation of nucleoside and nucleotide inhibitors, such as PSI-7851, that hold the potential for ...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

... 31 - November 4. ANA598 is the Company's investigational hepatitis C non- nucleoside polymerase inhibitor. ANA598 Phase I Study Results In the Phase I ... with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside polymerase inhibitor PSI-6130 (the active agent of R7128). These studies ...

Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients

... This approach represents a potential opportunity to preserve nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs), ... N Engl J Med 2007; 356: 1723-35. (10) The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in ...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

... to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that bind at the thumb site. In addition, ... interferon-alpha, a representative protease inhibitor and a representative nucleoside polymerase inhibitor. About ANA598 Preclinical evaluation of ANA598 ...

Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

... hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed in ... of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified ...

Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C

... approximately 15- to 20-fold greater than the in vitro potency of R7128, a nucleoside analog polymerase inhibitor of HCV that Pharmasset is developing through ... or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is ...

Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C

... 2 or 3 patients, this would demonstrate a distinct clinical attribute of nucleoside polymerase inhibitors." Please see http://www.clinicaltrials.gov or ... of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified ...

Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

... hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through ... of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified ...

Pharmasset Reports First Fiscal Quarter 2008 Financial Results

... for the treatment of HCV. -- Discovered a new series of proprietary nucleoside analogs that have demonstrated potent anti-HCV activity. ... activities. -- Conducting preclinical studies of a proprietary anti-HCV nucleoside analog to support first-in-human clinical trials, once a lead ...

Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers

... in Glasgow, Scotland. R7128 is a prodrug of PSI- 6130, an oral cytidine nucleoside analog polymerase inhibitor of hepatitis C virus (HCV) that is being ... demonstrated potency in preclinical studies. PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for ...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

... study group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35. 7 The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. ...

Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences

... of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration ...

TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics

... said TriLink CEO, Dr. Richard Hogrefe. About TriLink TriLink Biotechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp(TM) PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR ...

TriLink Launches CleanAmp(TM) dNTPs for Hot Start PCR

... compared to the modified enzymes available on the market." About TriLink TriLink BioTechnologies, Inc. manufactures custom oligonucleotides, nucleoside triphosphates and CleanAmp(TM) Products for research and diagnostic laboratories. In addition, custom chemistry, contract research services and GMP ...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

... to infection with e-antigen positive hepatitis B virus (QUASH 305) or e-antigen positive (QUASH 306) who have never been treated with drugs of the nucleoside class. The primary objective of the studies are to assess the effect of clevudine on reducing levels of virus in the blood and normalization of liver ...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... proprietary SEPA polymer technology, for the treatment of onychomycosis, a condition commonly known as nail fungus. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...

Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

... oral nucleotide prodrug candidate based on Idenix's proprietary liver-targeting technology. This technology enables the delivery of high levels of nucleoside triphosphate in the liver, potentially maximizing drug efficacy and limiting systemic side effects. In HCV genotype-1 infected chimpanzees, ...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

... currently not on treatment." About R7128 R7128, being developed for the treatment of chronic HCV infection, is a pro-drug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A pro-drug is a chemically modified form of a molecule designed to enhance the absorption, distribution and ...

Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy

... minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, and smoking). About Abacavir Abacavir sulfate is a nucleoside reverse transcriptase inhibitor with a proven safety and efficacy profile as part of an HIV treatment regimen. Abacavir is a key component in ...

Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic

... in both in vitro and in vivo preclinical models. Pre-clinical testing suggests that this technology enables the delivery of high levels of active nucleoside triphosphate into the liver, the site of primary HCV infection. In HCV genotype-1 infected chimpanzees, once-daily oral administration of 10 mg/kg of ...

Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

... virologic response (SVR) after being off of therapy for 24 weeks, the primary endpoint of the study. Clevudine is an oral, once-daily pyrimidine nucleoside analog that has been evaluated in 18 clinical trials in more than 800 individuals. Phase 3 studies are currently being conducted in approximately 140 ...

Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results

... development pipeline in all three therapeutic areas of focus, including: -- Announced positive preliminary results for RDEA806, our lead non- nucleoside reverse transcriptase inhibitor (NNRTI), in a Phase 2a monotherapy study in patients with human-immunodeficiency virus (HIV), demonstrating ...

Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research

... number of replicon mutations known to confer resistance to other anti-HCV agents currently in clinical development, including protease inhibitors and nucleoside polymerase inhibitors. This data confirms the broad potential utility of ANA598 to be used in combination with multiple other anti-HCV agents, ...

ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests

... Alberta on March 30, 2008. The preclinical results demonstrate a unique resistance profile for ANX-201 and suggest suppression of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class of drugs to treat HIV. The HIV Pathogenesis Conference is part of the Keystone ...
Other Contents
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
(Date:7/10/2014)... July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... Mr. Gino Pereira was interviewed on July 1 ... Tampa Florida . Mr. Pereira discusses the company,s ... Harris and how the Wocket™ aims to replace a ... Cedric Harris tells Gino he has never ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new ... (DW). An Asian OEM has selected FPC1021 for a flagship ... August 2014.   FPC is proud to announce ... planned date for start of mass production in August 2014. ... 5M, for delivery in the first half of July. The ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
(Date:7/12/2014)... By Dennis Thompson ... -- There,s no way to guarantee that a surgical technique ... tiny incisions won,t increase the risk of spreading cancer to ... Friday. The advisory panel to the Food and Drug ... -- called laparoscopic power morcellation -- should sign a written ...
(Date:7/12/2014)... 2014 In this cognitive ... assessment and training’ is defined as solution ... or enhance cognitive functions. These solutions are ... dementia screening, clinical trials, driver’s safety, rehabilitation, ... assessment, brain training, and employers’ assessment and ...
(Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... damage allegations continue to move forward in the ... Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... U.S. District Judge Lawrence F. Stengel has ordered ... other things, Judge Stengel found that the witness’s ...
(Date:7/12/2014)... News) -- If you make exercise fun, you,ll eat less ... 56 adults were led on a 1.4-mile walk and were ... scenic walk. The participants were given lunch after the walk, ... ate 35 percent more chocolate pudding for dessert than those ... another experiment, 46 adults were given mid-afternoon snacks after their ...
Breaking Medicine News(10 mins):Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Make Exercise Fun, Eat Less Afterwards 2
Other TagsOther Tags